» Articles » PMID: 19161194

Prediction of Locally Recurrent Prostate Cancer After Radiation Therapy: Incremental Value of 3T Diffusion-weighted MRI

Overview
Date 2009 Jan 24
PMID 19161194
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To prospectively evaluate the incremental value of diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps in addition to T2-weighted imaging (T2WI) for predicting locally recurrent prostate cancer in patients with biochemical failure after radiation therapy.

Materials And Methods: Thirty-six consecutive patients with an increased prostate-specific antigen level after radiation therapy underwent 3T MRI followed by transrectal biopsy. The MRI findings and biopsy results were correlated in sextant prostate sectors of peripheral zones (PZs). Two radiologists in consensus reviewed T2WI and combined T2WI and DWI with ADC maps, and rated the likelihood of recurrent cancer on a five-point scale. ADC values were calculated for recurrent cancer and benign tissue.

Results: Of 216 sectors, 65 prostate sectors (30%) were positive for cancer in 18 patients. For predicting recurrent cancer, combined T2WI and DWI showed a greater sensitivity compared to T2WI (P < 0.001). A significantly greater area under the receiver operating characteristics curve (Az) was determined for combined T2WI and DWI (Az = 0.879, P < 0.01) as compared to T2WI (Az = 0.612). Mean ADC values between recurrent cancer and benign tissue showed a statistically significant difference (P < 0.01).

Conclusion: For predicting locally recurrent prostate cancer after radiation therapy, the use of combined T2WI and DWI showed a better diagnostic performance compared to T2WI.

Citing Articles

Apparent Diffusion Coefficient as an Early Predictive Factor of Local and Overall Response to Treatment with Androgen Deprivation Therapy and Radiotherapy in Patients with Prostate Cancer.

Duque-Santana V, Fernandez J, Diaz-Gavela A, Recio M, Guerrero L, Pena M Cancers (Basel). 2025; 17(5).

PMID: 40075610 PMC: 11898613. DOI: 10.3390/cancers17050762.


The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer.

Pio F, Murdock A, Fuller R, Whalen M Cancers (Basel). 2024; 16(18).

PMID: 39335196 PMC: 11430134. DOI: 10.3390/cancers16183225.


Prostate Imaging for Local Recurrence Reporting and Data System for Biparametric Magnetic Resonance Imaging: A Proposal.

Scialpi M, Martorana E, Trippa F, Di Marzo A, Scalera G, Aisa M Urol Res Pract. 2023; 49(4):233-240.

PMID: 37877824 PMC: 10544277. DOI: 10.5152/tud.2023.22228.


Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI.

Yilmaz E, Harmon S, Belue M, Merriman K, Phelps T, Lin Y Eur J Radiol. 2023; 168:111095.

PMID: 37717420 PMC: 10615746. DOI: 10.1016/j.ejrad.2023.111095.


MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Menard C, Navarro-Domenech I, Liu Z, Joseph L, Barkati M, Berlin A Front Oncol. 2022; 12:971344.

PMID: 36091157 PMC: 9459480. DOI: 10.3389/fonc.2022.971344.